Last updated on June 2016

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors


Brief description of study

Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing and limited peripheral neuro-toxicity, two major potential advantages in patients with advanced NSGCTs. Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have demonstrated activity in pre-treated GCTs and are now part of standard treatment, but cabazitaxel has not yet been tested in patients with NSGCT.

Clinical Study Identifier: NCT02115165

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Karim FIZAZI, MD-PhD

Gustave Roussy Cancer Campus Grand Paris
Villejuif, France
  Connect »